These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28280607)

  • 21. Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.
    Methy N; Bedenne L; Bonnetain F
    BMC Cancer; 2010 Jun; 10():277. PubMed ID: 20537166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials.
    Petrelli F; Coinu A; Cabiddu M; Borgonovo K; Ghilardi M; Lonati V; Barni S
    Medicine (Baltimore); 2016 Jun; 95(26):e3997. PubMed ID: 27368007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.
    Xie W; Regan MM; Buyse M; Halabi S; Kantoff PW; Sartor O; Soule H; Clarke NW; Collette L; Dignam JJ; Fizazi K; Paruleker WR; Sandler HM; Sydes MR; Tombal B; Williams SG; Sweeney CJ;
    J Clin Oncol; 2017 Sep; 35(27):3097-3104. PubMed ID: 28796587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs.
    Gyawali B; Hey SP; Kesselheim AS
    EClinicalMedicine; 2020 Apr; 21():100332. PubMed ID: 32382717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis.
    Li Z; Shan F; Wang Y; Zhang Y; Zhang L; Li S; Jia Y; Xue K; Miao R; Li Z; Ji J
    PLoS One; 2018; 13(1):e0189294. PubMed ID: 29370182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Effectiveness and Safety of Open Versus laparoscopic Surgery for Rectal Cancer after Preoperative Chemo-radiotherapy: A Meta-Analysis.
    Zhang JJ; Guo BL; Zheng QX; Chen ZY
    Comb Chem High Throughput Screen; 2019; 22(3):153-159. PubMed ID: 30987563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma.
    Liu H; Wang Y; Qi C; Xie T; Peng Z; Li J; Shen L; Zhang X
    Front Oncol; 2022; 12():835389. PubMed ID: 35463354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer.
    Fokas E; Ströbel P; Fietkau R; Ghadimi M; Liersch T; Grabenbauer GG; Hartmann A; Kaufmann M; Sauer R; Graeven U; Hoffmanns H; Raab HR; Hothorn T; Wittekind C; Rödel C;
    J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Yang Y; Wang J; Wang W; Zhang T; Zhao J; Wang Y; Li Y; Wang L; Bi N
    Front Oncol; 2022; 12():810580. PubMed ID: 35155246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of Correlation Between Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies.
    Zhu R; Lu D; Chu YW; Chai A; Green M; Zhang N; Jin JY
    AAPS J; 2017 May; 19(3):669-681. PubMed ID: 28224402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surrogacy Beyond Prognosis: The Importance of "Trial-Level" Surrogacy.
    Buyse M; Saad ED; Burzykowski T; Regan MM; Sweeney CS
    Oncologist; 2022 Apr; 27(4):266-271. PubMed ID: 35380717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validity of Using Pathological Response as a Surrogate for Overall Survival in Neoadjuvant Studies for Esophageal Cancer: A Systematic Review and Meta-analysis.
    Su F; Yang X; Yin J; Shen Y; Tan L
    Ann Surg Oncol; 2023 Nov; 30(12):7461-7471. PubMed ID: 37400616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does A Longer Waiting Period After Neoadjuvant Radio-chemotherapy Improve the Oncological Prognosis of Rectal Cancer?: Three Years' Follow-up Results of the Greccar-6 Randomized Multicenter Trial.
    Lefèvre JH; Mineur L; Cachanado M; Denost Q; Rouanet P; de Chaisemartin C; Meunier B; Mehrdad J; Cotte E; Desrame J; Karoui M; Benoist S; Kirzin S; Berger A; Panis Y; Piessen G; Saudemont A; Prudhomme M; Peschaud F; Dubois A; Loriau J; Tuech JJ; Meurette G; Lupinacci R; Goasguen N; Creavin B; Simon T; Parc Y;
    Ann Surg; 2019 Nov; 270(5):747-754. PubMed ID: 31634178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Prognostic Value of a Pathologic Complete Response After Neoadjuvant Therapy for Digestive Cancer: Systematic Review and Meta-Analysis of 21 Studies.
    Wan T; Zhang XF; Liang C; Liao CW; Li JY; Zhou YM
    Ann Surg Oncol; 2019 May; 26(5):1412-1420. PubMed ID: 30805807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients.
    Goorts B; van Nijnatten TJ; de Munck L; Moossdorff M; Heuts EM; de Boer M; Lobbes MB; Smidt ML
    Breast Cancer Res Treat; 2017 May; 163(1):83-91. PubMed ID: 28205044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progesterone Receptors, Pathological Complete Response and Early Outcome for Locally Advanced Breast Cancer - a Single Centre Study. (PPLB - 01).
    Agrawal S; Banswal L; Saha A; Arun I; Datta SS; Chatterjee S; Ahmed R
    Indian J Surg Oncol; 2016 Dec; 7(4):397-406. PubMed ID: 27872526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant dose-dense chemotherapy for locally advanced breast cancer: a meta-analysis of published studies.
    Petrelli F; Coinu A; Lonati V; Cabiddu M; Ghilardi M; Borgonovo K; Barni S
    Anticancer Drugs; 2016 Aug; 27(7):702-8. PubMed ID: 27058707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trials.
    Blondeaux E; Xie W; Carmisciano L; Mura S; Sanna V; De Laurentiis M; Caputo R; Turletti A; Durando A; De Placido S; De Angelis C; Bisagni G; Gasparini E; Rimanti A; Puglisi F; Mansutti M; Landucci E; Fabi A; Arecco L; Perachino M; Bruzzone M; Boni L; Lambertini M; Del Mastro L; Regan MM
    EClinicalMedicine; 2024 Apr; 70():102501. PubMed ID: 38685923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.